Drug Interactions between belumosudil and lenacapavir
This report displays the potential drug interactions for the following 2 drugs:
- belumosudil
- lenacapavir
Interactions between your drugs
belumosudil lenacapavir
Applies to: belumosudil and lenacapavir
Lenacapavir may increase the blood levels and effects of belumosudil. The effect on belumosudil may last for up to 9 months after the last dose of lenacapavir. You may experience increased side effects as a result. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
belumosudil food
Applies to: belumosudil
Consumer information for this interaction is not currently available.
ADJUST DOSING INTERVAL: Administration with food increases the oral bioavailability of belumosudil. The mechanism has not been described. Administration of belumosudil (200 mg single oral dose) in healthy subjects, with a fatty and calorie-rich meal (approximately half of the calories were contained in the fat) increased the mean belumosudil peak plasma concentration (Cmax) and area under the concentration-time curve (AUC) by 120% and 100%, respectively, compared to administration under fasting conditions. The time to reach peak concentration (Tmax) was delayed by 30 minutes. Administration of oral belumosudil 200 mg once daily with food in patients with chronic graft-versus-host disease (chronic GVHD) lead to steady-state concentrations of the drug with an accumulation ration of 1.4.
MANAGEMENT: To ensure maximal oral absorption, belumosudil should be administered with a meal, every day at the same time.
References
- (2024) "Product Information. Rezurock (belumosudil)." Sanofi
- (2024) "Product Information. Rezurock (belumosudil)." Kadmon Pharmaceuticals, 11/2023
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.